Breaking News Instant updates and real-time market news.

ONCS

OncoSec

$1.73

-0.14 (-7.49%)

08:25
11/06/18
11/06
08:25
11/06/18
08:25

OncoSec to hold a conference call

Management reviews preliminary clinical and immunological data from the Company's ongoing KEYNOTE-695 study, which will be presented at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting, on a conference call to be held on November 6 at 8:30 am. Webcast Link

  • 06

    Nov

  • 07

    Nov

  • 27

    Nov

ONCS OncoSec
$1.73

-0.14 (-7.49%)

10/15/18
PIPR
10/15/18
NO CHANGE
Target $5
PIPR
Overweight
Piper reiterates Overweight on OncoSec with $5 price target
Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on OncoSec Medical with a $5 price target after the company announced it initiated a Phase II study of tavokinogene telseplasmid plus Keytruda in and triple negative breast cancer patients who have received one prior chemo or immunotherapy with preliminary data in 2019. The primary driver for OncoSec shares remains the Stage 1 Phase IIb Pisces data on tavokinogene telseplasmid plus Keytruda in PD-1 refractory melanoma in November, Tenthoff tells investors in a research note. He points out that depending on the data, OncoSec may initiate Stage 2 of the study, which could serve as the basis for accelerated approval in melanoma in 2020.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $5
PIPR
Overweight
OncoSec price target raised to $5 from $4 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for OncoSec Medical to $5 saying tavokinogene telseplasmid has demonstrated proof-of-concept data in relapsed/refractory melanoma. The analyst expects final Phase II OMS-100 monotherapy plus preliminary Phase IIb data at the Society for Immunotherapy of Cancer meeting in November. Depending upon the strength of data in Stage 2 of this trial, OncoSec may be able to seek accelerated approval in melanoma in 2020, Tenthoff tells investors in a research note after taking over coverage of the name. He maintains Piper's Overweight rating on OncoSec.
02/09/18
PIPR
02/09/18
INITIATION
Target $4
PIPR
Overweight
OncoSec initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started OncoSec Medical with an Overweight rating and $4 price target. The company's lead candidate ImmunoPulse in checkpoint inhibitor refractory metastatic melanoma "offers a differentiated approach," the analyst contends. He sees potential for $350M in peak U.S. revenues for IP IL-12 in this initial population following a 2020 launch.

TODAY'S FREE FLY STORIES

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

12:17
11/20/18
11/20
12:17
11/20/18
12:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

12:16
11/20/18
11/20
12:16
11/20/18
12:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BSX

Boston Scientific

$34.13

-1.16 (-3.29%)

12:10
11/20/18
11/20
12:10
11/20/18
12:10
Options
Puts lead calls 4:1 in Boston Scientific as implied volatilities lift »

Puts lead calls 4:1 in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 27

    Nov

12:10
11/20/18
11/20
12:10
11/20/18
12:10
General news
U.S. equities remain under pressure »

U.S. equities remain…

AMAT

Applied Materials

$36.27

1.85 (5.37%)

12:05
11/20/18
11/20
12:05
11/20/18
12:05
Options
Applied Materials call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

12:05
11/20/18
11/20
12:05
11/20/18
12:05
General news
FX Action: USD-CAD »

FX Action: USD-CAD…

FB

Facebook

$133.04

1.42 (1.08%)

12:02
11/20/18
11/20
12:02
11/20/18
12:02
Hot Stocks
Facebook experiencing service issues »

Visiting Facebook.com…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

EGRX

Eagle Pharmaceuticals

$48.01

-1.36 (-2.75%)

12:01
11/20/18
11/20
12:01
11/20/18
12:01
Conference/Events
Eagle Pharmaceuticals management to meet with RBC Capital »

Group Dinner Meeting to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 27

    Nov

  • 02

    Dec

SDRL

Seadrill

$14.63

-1.84 (-11.17%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Seadrill falls -11.2% »

Seadrill is down -11.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EROS

Eros International

$8.19

-1.16 (-12.41%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Eros International falls -12.4% »

Eros International is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 20

    Dec

LB

L Brands

$30.23

-4.3 (-12.45%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
L Brands falls -12.5% »

L Brands is down -12.5%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

SCO

Scor ADR

$23.44

2.26 (10.67%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Scor ADR rises 10.9% »

Scor ADR is up 10.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOAH

Noah Holdings

$45.61

4.81 (11.79%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Noah Holdings rises 11.3% »

Noah Holdings is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DWT

Britannia Bulk

$11.85

1.62 (15.84%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Hot Stocks
Britannia Bulk rises 16.1% »

Britannia Bulk is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BECN

Beacon Roofing

$28.44

0.7 (2.52%)

12:00
11/20/18
11/20
12:00
11/20/18
12:00
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX raises FY19 revenue view to $38.6B-$38.7B from $38.2B-$38.4B »

Consensus $38.44B. Sees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

TJX

TJX

$46.84

-2.13 (-4.35%)

11:58
11/20/18
11/20
11:58
11/20/18
11:58
Earnings
TJX sees Q4 revenue $10B-$10.9B, consensus $10.92B »

Says guidance assumes a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

UNP

Union Pacific

$142.91

-7.74 (-5.14%)

11:55
11/20/18
11/20
11:55
11/20/18
11:55
Options
Union Pacific put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

11:53
11/20/18
11/20
11:53
11/20/18
11:53
Conference/Events
William Blair industrial technology analysts to hold a group luncheon »

Group Luncheon Meeting to…

BECN

Beacon Roofing

$28.34

0.6 (2.16%)

11:52
11/20/18
11/20
11:52
11/20/18
11:52
Downgrade
Beacon Roofing rating change  »

Beacon Roofing downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

11:51
11/20/18
11/20
11:51
11/20/18
11:51
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
Conference/Events
UBS alternative energy analyst to hold an analyst/industry conference call »

Alternative Energy…

11:45
11/20/18
11/20
11:45
11/20/18
11:45
General news
U.S. sold $50 B 4-week T-bills at a 2.20% high rate »

U.S. sold $50 B 4-week…

11:43
11/20/18
11/20
11:43
11/20/18
11:43
Conference/Events
William Blair industrials & business services analysts hold dinner meeting »

Analysts hold a year-end…

BBY

Best Buy

$63.57

1.38 (2.22%)

11:42
11/20/18
11/20
11:42
11/20/18
11:42
Recommendations
Best Buy analyst commentary  »

Best Buy 'continued…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 05

    Dec

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.